40 results about "Treatment intervention" patented technology

An interactive computer assisted method compiles comprehensive health care information on patients in a central repository, assesses and analyzes this information, and identifies high utilizers of health care services using a computer and a user associated therewith. The method includes the steps of creating a central repository of various databases containing patient information, including demographic information and behavior, and optionally the results of a core survey of health status questions. The invention optionally involves the step of determining the appropriate core questions and the criteria to determine whether and when to ask certain questions of particular patients based on their response to prior questions. The invention accurately predicts risk of a medical condition or progression of a medical condition utilizing an interactive administration of a set of core survey questions combined with diagnostic data and places patients efficiently, reliably, and accurately into the appropriate treatment intervention programs. The invention eliminates redundant, repetitive surveying of patients with multiple medical conditions.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

An apparatus and method for stimulating the neurochemistry of the brain including enzymes, nucleosides, nucleotides, neuropeptides, neurotransmitters, amino acids, brain glucose, steroids, and hormones, and more specifically, an apparatus and method for enhancing overall brain function, including cognitive abilities and intelligence quota (IQ). Other treatment interventions the apparatus and method can positively affect include neurological, physiological, and psychological disorders and diseases. The inventive method utilizes a specially designed goggle which contains two round eye pieces to which are attached the light assemblies. These light assemblies are comprised of 1-20 white full spectrum lights which are directed toward both eyes, within a two inch radius of the retina to avoid overstimulation. The goggle has an expandable nose piece with a mechanism to allow the eye pieces to swing outward and adjust over the eye of any individual, in accordance with the specified retinal placement. The inset lights flash or flicker utilizing intermittent “fuzzy” light, and encompass frequencies ranging from 1-1200 Hz (cycles per second), specifically excluding the range between 55-65 Hz to prevent any form of seizure. The light stimulus is accompanied by unmatched, intermittent sound stimulation, called “fuzzy” sound. The sound is audible through the use of any type headphone. The method is in the form of computerized programs, and includes a variety of formulas translated as “sessions” to be downloaded into any existing light / sound device or apparatus. These formulas are in the form of a variety of sessions, lasting no more than 40 minutes each, to address and or treat a variety of symptoms, disorders, and diseases. The sessions control the light goggle apparatus and sound. Neither the “fuzzy” light nor the “fuzzy” sound are synchronized.

An interactive computer assisted method compiles comprehensive health care information on patients in a central repository, assesses and analyzes this information, and identifies high utilizers of health care services using a computer and a user associated therewith. The method includes the steps of creating a central repository of various databases containing patient information, including demographic information and behavior, and optionally the results of a core survey of health status questions. The invention optionally involves the step of determining the appropriate core questions and the criteria to determine whether and when to ask certain questions of particular patients based on their response to prior questions. The invention accurately predicts risk of a medical condition or progression of a medical condition utilizing an interactive administration of a set of core survey questions combined with diagnostic data and places patients efficiently, reliably, and accurately into the appropriate treatment intervention programs. The invention eliminates redundant, repetitive surveying of patients with multiple medical conditions.

The invention belongs to the technical field of computers, and relates to a rehabilitation therapy determination method and device, a computer readable storage medium and electronic equipment. The method comprises the following steps: acquiring a target index and an object identifier, and sending a parameter acquisition request carrying the object identifier; receiving a target index parameter corresponding to the target index based on the parameter acquisition request; inputting the target index parameter into a pre-trained machine learning model to enable the machine learning model to outputa target therapy; obtaining an evaluation standard corresponding to the target index, and if the target index parameter does not meet the evaluation standard, generating early warning information corresponding to the target therapy; and adjusting the target therapy according to the early warning information so as to carry out corresponding rehabilitation training. On one hand, medical staff monitor target index parameters of an object in real time and know the health condition of the object; on the other hand, accurate treatment measures and methods are recommended to medical staff, passive rescue is changed into active intervention treatment, and great influences are achieved on prevention against serious diseases.

A system and method to plan medical diagnosis and / or therapy procedures is provided. The method includes electronic recording of a patient anamnesis (medical history), electronic recording of a patient finding, automatic generation of a keyword list dependent on the patient anamnesis and the patient finding by access to a keyword databank, automatic generation of diagnosis and / or therapy measure list dependent on keywords of the keyword list under access to a medical databank, automatic assessment of diagnosis and / or therapy measures of the diagnosis and / or therapy measure list under access to a case databank, automatic temporal pre-allocation of resources necessary for the implementation of diagnosis and / or therapy measures, dependent on a result of the assessment of the diagnosis and / or therapy measures under access to a resource databank, automatic generation of at least one diagnosis and / or therapy procedure dependent on the pre-allocation of resources, automatic generation of an electronic checklist with diagnosis and / or therapy measures and temporal pre-allocation of resources necessary for implementation of these diagnosis and / or therapy measures. The method allows flexible planning adapted to the current availability of resources and, via the immediate enlistment of expertise, ensures a consistent quality of the diagnosis and / or therapy planning.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

The invention discloses a tumour treatment intervention apparatus including a needle tubing and a support seat, the needle tubing is plugged into a circular hole left in the middle of the support seat, the pipe walls at the two sides of the needle tubing are provided with tooth bars, the inner cavities at the two sides of the support seat are provided with grooves, the walls of the grooves are connected with ratchet wheels and pawls through shafts, the pawls are arranged at the upper sides of the ratchet wheels, the pawls are engaged with one sides of the ratchet wheels, and the other sides of the ratchet wheels are engaged with the tooth bars, and the inner end parts of adjusting rods are hinged to the upper ends of the pawls. The intervention apparatus controls the distance of the syringe needle inserting into the human body through the ratchet wheel and tooth bar structure, so that the distance from the syringe needle to the pathological part is controlled in high precision. By means of the support leg structure, the use stability of the intervention apparatus is improved, and by means of the support leg telescoping structure, the intervention apparatus can make adjustment according to different body parts, so that the use scope of the apparatus is enlarged. In addition, the intervention apparatus has the advantages of simple use, high precision, and low cost.

Based on the discovery of a group of 11 prognostic related gene profiles in serous ovarian cancer and the detection of the expression level of the 11 prognostic related gene profiles in clinical tumorsamples, the prognostic score of a patient is calculated according to the prognostic correlation coefficient of a group of the genes to evaluate the clinical prognosis of ovarian cancer patients andrelated application of the clinical prognosis. The system can assist in evaluating the response of the ovarian cancer patients to treatment interventions, thus whether the patients benefit from chemical or targeted treatments or not is judged, treatment choice is conducted, excessive medical treatment is avoided, and the purpose of personalized treatment is achieved. According to the system and different detection technology platforms, corresponding 11 gene expression measurement kits are designed and developed.

Occasionally relevant findings and important recommendations made within medical or radiology reports fail to elicit the appropriate follow-up due to multiple factors. The clinician may miss the recommendation or lose track of it while addressing a more acute illness, the recommendation may have not been conveyed to the patient, or the patient may fail to schedule or show-up for the subsequent exam. Prior literature indicates that a significant percentage of scheduled appointments result in no-shows or cancellations by patients, and a small but significant percentage of indicated follow-up studies are thus not obtained. Such omissions occasionally result in adverse consequences suffered by the patients, and increase the risk of legal liabilities to the clinicians or radiologists. A method and system is presented that identifies patients who did not obtain such recommended diagnostic tests or therapeutic interventions, and which sorts and filters the detected patients according to relevance of the recommendation, optionally discarding recommendations of low relevance, and facilitates the management of the detected patients.

The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and / or life threatening response to illness and / or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and / or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and / or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and / or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

The invention discloses an application of a group of gastric cancer genes. In the invention, based on a group of 53 prognosis related genes in gastric cancer and the detection results of the expression levels thereof in clinical samples, the score is calculated and predicted to evaluate clinical prognosis of gastric cancer as well as related application thereof. The system can help the gastric cancer patients in treatment selection and can predict the reaction to treatment intervention so as to judge whether the patients profit from chemical and targeted therapy, excessive medication is avoided, the medical cost is reduced, and finally, an aim of accurate or individualized medicine is achieved. According to the system and different detection technology platforms, corresponding 53 gene expression measurement kits are designed and developed.

The invention discloses an augmented reality technology-based autistic child interest point information collection system. The system comprises a reality scene building module, a database module for storing personal information of autistic children, a virtual reality combination module, a display module, an interactive module and an information statistics module. Firstly an autistic child scans chartlets in a built reality scene by using a mobile device; an augmented reality technology is used for superposing augmented information (three-dimensional models or videos) corresponding to the chartlets on a picture; the autistic child operates the augmented information; and finally, a background system performs statistics on time of operating the augmented information by the autistic child and judges interest preferences of the autistic child according to the lengths of the time of operating various augmented information by the autistic child, thereby realizing later treatment intervention. According to the system, the autism treatment intervention is effectively carried out, so that a therapist of the autistic child can obtain patient information more conveniently, and the autistic child can better integrate into society to learn new knowledge.

The invention provides a visual cortex positioning method with transcranial magnetic stimulation. The stimulation intensity correction and the stimulation target positioning are based on the special sensory perception characteristic of the visual cortex, the double information of the visual cortex function and the anatomical structure of a person to be stimulated is obtained, and the positioning is accurate. The invention provides a keyboard connected to an rTMS parameter console, keys replace oral input so as to reduce the possibility of head movement, further increase the positioning accuracy and improve the efficiency of next treatment intervention. According to the invention, starting from the mean intensity of the stimulation threshold PT, the intensity is increased by 2% step by stepalong with retest reliability test method, three areas of information of brain appearance, brain anatomical structure and brain functional area positioning of the person to be stimulated is fully integrated, the positioning accuracy is ensured, and the method is superior to a TMS positioning method which is carried out by simply utilizing the brain information in one aspect in the prior art.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and / or life threatening response to illness and / or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and / or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and / or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and / or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

A healthcare management system is provided. The system may include a memory configured to store health-related information about individual members of a population and a processor operatively coupled to the memory. The processor may be configured to select a first treatment intervention for addressing predetermined symptoms of an individual member of the population from two or more potential treatment interventions. The processor may be configured to select the first treatment intervention based on information stored in the memory, such as a determined risk that the symptoms are caused by one or more predetermined health conditions. In addition, the processor may be configured to select the first treatment intervention based on at least one of the following factors: a success rate of each potential treatment intervention at treating the one or more predetermined health conditions; and a cost of each potential treatment intervention. The system may also include an output module configured to provide information regarding the first treatment intervention to at least one of a healthcare provider and an insurer of the individual member.

The invention belongs to the technical field of biology, and relates to a gene marker and a detection kit for predicting the clinical efficacy of methotrexate in the treatment of psoriasis. A LCE3D SNP site rs4112788AG genotype is used as a gene marker for predicting that clinical efficacy of methotrexate in treating psoriasis. The relationship between the LCE3D SNP site rs4112788AG genotype and clinical efficacy of MTX in the treatment of psoriasis is studied. The results showed that rs4112788 genotype is related to clinical efficacy of MTX. The kit is provided to investigate the efficacy ofMTX therapy and the risk of hepatotoxicity in psoriasis patients with or without the rs4112788AG genotype at the LCE3D SNP locus, predict and evaluate the clinical efficacy of MTX in the treatment ofpsoriasis, thus guiding clinicians to formulate appropriate MTX treatment intervention program and providing a basis for improving the clinical efficacy of MTX.

The invention discloses an antibody IgG against Staphylococcus aureus serine-rich repeat protein SraP and application. The antibody can specifically bind to an L-Lectin motif of the serine-rich repeatprotein, can bind to Staphylococcus aureus surface anchored protein SraP to reduce cell adhesion and invasion of Staphylococcus aureus and the number of bacteria in blood of mice, and can be used asan action target for an anti-Staphylococcus aureus infection antibody in treatment intervention.

The invention belongs to the field of biotechnology, relates to a novel genetic marker that predicts clinical efficacy and side effects of MTX. Through studying the relationship between TNIP1 SNP siters10036748 genotype and MTX treatment psoriasis clinical curative effect and liver function damage / liver fibrosis index abnormality, the rs10036748 TT genotype of TNIP1 SNP locus is proposed as a genetic marker to predict the clinical efficacy of MTX in the treatment of psoriasis and liver damage. A detection kit for predicting that clinical efficacy and side effect of methotrexate in the treatment of psoriasis is further provided. The marker and the kit can be used for predicting the clinical curative effect and side effect evaluation of MTX in treating psoriasis, are helpful for guiding clinicians to formulate a suitable MTX treatment intervention scheme, and provide a basis for improving the clinical efficacy of methotrexate and reducing toxicity and side effects.

The invention discloses a hand and foot meridian regulating machine. The hand and foot meridian regulating machine comprises a housing, wherein the housing adopts a transparent cylinder structure, anend port is formed in one end of the housing and protrudes from the outside wall of the housing, and a plurality of functional module mounting holes are formed in the outer side of the housing. A cavity is subjected to operations of pumping, inflating and the like, pressure changes on the surface of the skin of a human body, contained in the cavity, can be realized, so that the muscle, meridians,tendons and bones in the position can be comprehensively relaxed or compressed, and external treatment intervention useful for meridian dredging for the human body can be generated. The hand and footmeridian regulating machine does not omit tiny joint meridians for hands and feet, the transparent housing can enable the limbs to be conveniently observed, and more visual convenient and humanized operations can be realized. An emergency air escape can prevent accidents.

The invention discloses a prognostic marker of squamous cell carcinoma, an establishment method of a prognostic risk assessment model and application of the prognostic marker and the prognostic risk assessment model, compared with single gene expression detection of squamous cell carcinoma in the prior art, the prognostic marker and the prognostic risk assessment model have higher specificity and higher diagnosis efficiency, can remarkably improve the detection sensitivity and specificity, and can be used for detecting squamous cell carcinoma. The method can accurately, conveniently and efficiently provide effective treatment measures for squamous cell carcinoma patients and improve prognosis, has good clinical application value, has the advantages of high sensitivity, good specificity and high accuracy, can provide effective guidance for clinicians to make treatment decisions on the squamous cell carcinoma patients, reduces the occurrence of invalid treatment, and has a wide application prospect. Therefore, treatment cost and discomfort experience of patients are reduced, long-term prognosis of squamous cell carcinoma patients can be improved, and social disease burden is expected to be relieved.

The embodiments of the present disclosure disclose an information generation method and device. First, at least one treatment intervention technique text of a target user is sorted in chronological order to obtain a treatment intervention technique text sequence L[C 1 , C 2 , C 3 ...C n ]; the text sequence L[C 1 , C 2 , C 3 ...C n ] input to the pre-trained recurrent neural network for prediction, the last element C in the output sequence n The Next Therapeutic Intervention Technique Text C n+1 ; and then input each obtained sequence of treatment intervention technical texts into the pre-trained recurrent neural network for prediction, and after cyclic execution of preset times m times, a sequence L[C 1 , C 2 , C 3 ...C n , C n+1 ,...C n+m ], using the historical treatment intervention technical text based on the target user can quickly predict the treatment intervention technical text in the next stage.

One or more embodiments of the invention provide a clinical decision-making method and device, and the clinical decision-making method comprises the steps: obtaining a sample data set of a plurality of observed objects for a preset disease, and the sample data set comprises the data features of the observed objects; clustering based on data features in the sample data set to obtain a plurality ofclustering groups; obtaining an end point event of the observed object in each clustering group; determining a target clustering group from the plurality of clustering groups according to the physiological indexes of the observed object in the end point event; acquiring data characteristics of the patient; according to the correlation between the data characteristics of the patient and the data characteristics of the observed objects in the target clustering group, carrying out clinical decision making on the patient. According to the method, clinical decision making can be carried out on thepatient by referring to treatment measures of the observed objects in the target clustering group; therefore, the targeted, practical and effective treatment measures can be provided for patients.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and / or life threatening response to illness and / or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and / or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and / or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and / or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

The invention belongs to the field of biotechnology, relates to psoriasis susceptibility genes and uses thereof, and particularly relates to psoriasis susceptibility genes LCE3D and TNIP1 and use thereof in preparing a detection kit. The invention provides new gene markers especially LCE3D SNP locus rs4112788AG genotype and TNIP1 SNP locus rs10036748TT genotype for predicting MTX clinical treatment effect, the new gene markers can be used as gene markers for predicting the clinical efficacy and toxic side effects of MTX intervention in the treatment of psoriasis; the invention also provides the detection kit. The kit predicts the clinical efficacy and side effects of MTX by detecting SNP loci in the psoriasis susceptibility genes LCE3D and TNIP1. The kit can be further used to predict theclinical efficacy and side effects of the MTX in the treatment of the psoriasis, and helps clinicians to develop appropriate MTX treatment intervention schedules.

The invention discloses a corresponding relation processing method and system based on patient perception and treatment measures; and the method comprises the steps of: obtaining a first parameter from a patient, wherein the first parameter is obtained when the patient is treated, and the first parameter is a physiological parameter of the patient; determining the perception of the patient according to the first parameter, wherein the perception is used for indicating the degree of pain perceived by the patient during treatment; acquiring treatment measures taken when the patient is treated; and determining a first corresponding relation between the treatment measures and the perception of the patient. According to the invention, the problem that how to utilize the pain degree sensed by the patient is not involved in the prior art is solved; the corresponding relation between the pain and the treatment measures is established; and data support is provided for further processing.